The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Is The Market Size Of The Pulmonary Arterial Hypertension Market Expected To Change Between 2026 And 2030?
The pulmonary arterial hypertension market has demonstrated substantial growth in recent years. It is anticipated to increase from $9.15 billion in 2025 to $9.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.6%. This historical growth can be attributed to several factors, including the rising prevalence of pulmonary arterial hypertension, inadequate early diagnosis capabilities, significant unmet medical needs, the availability of conventional drugs, and increasing awareness among healthcare professionals.
The pulmonary arterial hypertension market is anticipated to experience substantial growth in the upcoming years, with projections indicating it will expand to $13.75 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.5%. This expected market expansion during the forecast period is driven by factors such as the introduction of novel therapies, the broadened adoption of telemedicine, increasing governmental healthcare initiatives, a rise in the use of combination therapies, and the proliferation of specialized treatment centers. Significant trends observed during this period include personalized pulmonary hypertension treatments, advanced drug delivery systems, the ongoing development of combination therapies, the integration of telehealth and remote patient monitoring, and the emergence of new regional treatment centers.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp
What Drivers Are Expected To Influence The Pulmonary Arterial Hypertension Market During The Forecast Period?
The increasing number of clinical trials dedicated to drug development is anticipated to drive the expansion of the pulmonary arterial hypertension market moving forward. These clinical trials are research endeavors conducted to assess the safety, effectiveness, and potential adverse reactions of new drugs or treatments in humans. For pulmonary arterial hypertension, clinical trials for drug development can facilitate the creation of novel and more potent treatments, thereby enhancing patients’ quality of life, boosting safety and efficacy, providing earlier access, and helping to identify cost-effective treatment options. For instance, in May 2023, according to Xtalks, a Canada-based company specializing in providing life science webinars and virtual events, there are 452,604 clinical studies that have been registered on ClinicalTrials.gov as of May 17, 2023. Out of this total, 64,838 studies are actively seeking participants, which marks an increase from 365,000 registered trials in 2021. Therefore, the growing number of clinical trials for drug development is fueling the growth of the pulmonary arterial hypertension market.
How Is The Pulmonary Arterial Hypertension Market Structured Across Different Segments?
The pulmonary arterial hypertension market covered in this report is segmented –
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational
3) By Distribution channel: Retail, Online
Subsegments:
1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan
2) By PDE-5 Inhibitors: Sildenafil, Tadalafil
3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By SGC Stimulators: Riociguat, Vericiguat
Which Trends Are Shaping The Future Of The Pulmonary Arterial Hypertension Market?
Leading companies operating in the pulmonary arterial hypertension market are developing advanced products, such as OPSYNVI, to offer improved treatment options that enhance patient outcomes and overall quality of life for individuals affected by this serious condition. For instance, in March 2024, Johnson & Johnson, a US-based multinational company specializing in pharmaceuticals, biotechnology, and medical technologies, launched OPSYNVI for the chronic treatment of adults with pulmonary arterial hypertension. OPSYNVI can be utilized for patients with pulmonary arterial hypertension (PAH) who are either initiating therapy or already using an endothelin receptor antagonist (ERA) or PDE5 inhibitor, or both. It is also appropriate for those on stable doses of macitentan 10 mg and tadalafil 40 mg, administered as separate tablets.
Which Major Players Dominate The Pulmonary Arterial Hypertension Market?
Major companies operating in the pulmonary arterial hypertension market are United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Merck KGaA, Novartis International AG, Bristol-Myers Squibb Company, AstraZeneca plc, Daiichi Sankyo Company Limited
Read the full pulmonary arterial hypertension market report here:
Which Region Is Forecast To Lead The Pulmonary Arterial Hypertension Market In Terms Of Market Size?
North America was the largest region in the pulmonary arterial hypertension market in 2025. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Pulmonary Arterial Hypertension Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=5954&type=smp
Browse Through More Reports Similar to the Global Pulmonary Arterial Hypertension Market 2026, By The Business Research Company
Pulmonary Arterial Hypertension Market Report 2026
Pulmonary Arterial Hypertension Market Report 2026
Pulmonary Embolism Market Report 2026
https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model